Dr Michael Moore holds PhD and DSc degrees from the University of Nottingham and is a Fellow of the Royal College of Pathologists. His long academic career was based largely at the Paterson Institute for Cancer Research and Manchester University and he retains a post as Professor Associate in the Department of Cancer Genetics and Pharmacogenomics at the Brunel Institute. Dr Moore became a Director of Xenova Group plc in 1994 and Chief Scientific Officer in 1998, during tenure of which Xenova relinquished its drug discovery subsidiary to Terragen and acquired biologics company, Cantab Pharmaceuticals. In 2003, he was appointed Chief Executive Offier of Piramed Limited, a private UK-based biotechnology company dedicated to the discovery and development of PI 3-kinase inhibitors for cancer and immune-inflammatory disease. Piramed was acquired by Roche in 2008. Dr Moore was Chairman of Myotec Therapeutics prior to the merger with Hybrid BioSystems to create PsiOxus Therapeutics and is presently Executive Chairman of Cambridge-based MISSION Therapeutics and a Non-Executive Director of Chronos Therapeutics, BLiNK Therapeutics and Stem Cell Therapeutics. He is an immediate past Chairman of Cancer Research UK’s drug discovery committee.